You are here

Share:

Search Technologies

Showing 1-2 of 2 results found

Treatment of GPR101-Related, Growth Hormone-Related Disorders Such as Gigantism, Dwarfism or Acromegaly

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have developed a cell line that stably over-expresses GPR101. GPR101 inhibitors and agonists may be used to treat gigantism, acromegaly or dwarfism. The NICHD seeks licensing and/or co-development research partners to collaborate on the identification and characterization of GPR101 inhibitors (antagonists and inverse agonists) and agonists with the goal of identifying agents to treat gigantism, acromegaly or dwarfism.